Feinberg Larry N is Buying Biolase Inc. (NASDAQ:BIOL) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Biolase Inc. (NASDAQ:BIOL) reported that Feinberg Larry N has picked up 15,472,847 of common stock as of 2017-04-21.

The acquisition brings the aggregate amount owned by Feinberg Larry N to a total of 15,472,847 representing less than 22.58% stake in the company.

For those not familiar with the company, BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.

A glance at Biolase Inc. (NASDAQ:BIOL)’s key stats reveals a current market capitalization of 85.94 Million based on 67.66 Million shares outstanding and a price at last close of $1.29 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2015-10-21 Schuler picked up 33,762 at a purchase price of $0.95. This brings their total holding to 4,213,429 as of the date of the filing.

On the sell side, the most recent transaction saw Mulder unload 5,000 shares at a sale price of $1.25. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Biolase Inc. (NASDAQ:BIOL) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Guess Who Picked Nexvet Biopharma Plc. (NASDAQ:NVET) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Nexvet Biopharma Plc. (NASDAQ:NVET) reported that Farallon Capital has picked up 1,046,345 of common stock as of 2017-04-19.

The acquisition brings the aggregate amount owned by Farallon Capital to a total of 1,046,345 representing a 8.7% stake in the company.

For those not familiar with the company, Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company’s platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal’s immune system, a property referred to as 100% species-specificity. PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals. Biologics generally include mAbs, which are targeted antibodies derived from identical (clonal) cells. The Company’s advanced product candidates are in pivotal-phase development: ranevetmab (or NV-01) and frunevetmab (or NV-02).

A glance at Nexvet Biopharma Plc. (NASDAQ:NVET)’s key stats reveals a current market capitalization of 77.57 Million based on 11.75 Million shares outstanding and a price at last close of $6.61 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-03-04, Gearing picked up 9,000 at a purchase price of $3.35. This brings their total holding to 125,903 as of the date of the filing.

On the sell side, the most recent transaction saw Farrell unload 132 shares at a sale price of $3.27. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Nexvet Biopharma Plc. (NASDAQ:NVET) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Here’s Who Just Picked Up Musclepharm Corp (OTCMKTS:MSLP) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Musclepharm Corp (OTCMKTS:MSLP) reported that Amerop Holdings, Inc. has picked up 2,136,781 of common stock as of 2017-04-19.

The acquisition brings the aggregate amount owned by Amerop Holdings, Inc. to a total of 2,136,781 representing a 15.15% stake in the company.

For those not familiar with the company, MusclePharm Corporation is a performance lifestyle company. The Company develops, manufactures, markets and distributes branded nutritional supplements. The Company offers a range of powders, capsules, tablets and gels. The Company’s portfolio of brands targets various types of fitness enthusiasts, including professional, combat sport, weight training, bodybuilding, running, basketball, soccer, cross fit, golf, tennis, volleyball and other active lifestyle activities. The MusclePharm Sport Series includes supplements that cover the needs of athletes, including their workout needs. MusclePharm Hybrid Series products include Assault, Amino1 and Combat Protein Powder. FitMiss products are designed and formulated for the active woman’s lifestyle utilizing ingredients that cover the range of busy women’s needs, including weight loss, multi-vitamins, protein shakes, detox, skin care and pre-workout energy mixes. MusclePharm Core products include BCAA 3:1:2, CLA Core and Fish Oil.

A glance at Musclepharm Corp (OTCMKTS:MSLP)’s key stats reveals a current market capitalization of 30.34 Million based on 14.11 Million shares outstanding and a price at last close of $2.15 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-04-10, Amerop picked up 14,000 at a purchase price of $2.15. This brings their total holding to 2,136,781 as of the date of the filing.

On the sell side, the most recent transaction saw Bluher unload 3,000 shares at a sale price of $9.10. This brings their total holding to 190,118.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Musclepharm Corp (OTCMKTS:MSLP) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Ocera Therapeutics Inc. (NASDAQ:OCRX) is Attracting Smart Money

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ocera Therapeutics Inc. (NASDAQ:OCRX) reported that Perceptive Advisors has picked up 2,150,000 of common stock as of 2017-04-17.

The acquisition brings the aggregate amount owned by Perceptive Advisors to a total of 2,150,000 representing approximately 9.11% stake in the company.

For those not familiar with the company, Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.

A glance at Ocera Therapeutics Inc. (NASDAQ:OCRX)’s key stats reveals a current market capitalization of 37.96 Million based on 23.60 Million shares outstanding and a price at last close of $1.45 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-03-28, Byrnes picked up 3,000 at a purchase price of $1.28. This brings their total holding to 13,000 as of the date of the filing.

On the sell side, the most recent transaction saw Powell unload 11,969 shares at a sale price of $2.53. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Ocera Therapeutics Inc. (NASDAQ:OCRX) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Ronin Capital, Llc is Buying Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) reported that Ronin Capital, Llc. has picked up 95,059 of common stock as of 2017-04-17.

The acquisition brings the aggregate amount owned by Ronin Capital, Llc. to a total of 95,059 representing approximately 5.8% stake in the company.

For those not familiar with the company, Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. Bavituximab is its lead immunotherapy candidate. Bavituximab is a monoclonal antibody that targets and binds to phosphatidylserine (PS), a immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then flips and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. The Company’s subsidiary is Avid Bioservices, Inc. (Avid). Avid provides integrated current good manufacturing practices (cGMP) services from cell line development to commercial biomanufacturing.

A glance at Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM)’s key stats reveals a current market capitalization of 158.77 Million based on 297.71 Million shares outstanding and a price at last close of 0.546 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2012-03-14, Swartz picked up 16,000 at a purchase price of $0.62. This brings their total holding to 126,000 as of the date of the filing.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Schuler Jack W Picked Up Biolase Inc. (NASDAQ:BIOL) Shares

cfms

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Biolase Inc. (NASDAQ:BIOL) reported that Schuler Jack W has picked up 20,728,060 of common stock as of 2017-04-17.

The acquisition brings the aggregate amount owned by Schuler Jack W to a total of 20,728,060 representing approximately 28.71% stake in the company.

For those not familiar with the company, BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.

A glance at Biolase Inc. (NASDAQ:BIOL)’s key stats reveals a current market capitalization of 93.50 Million based on 67.66 Million shares outstanding and a price at last close of $1.32 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2015-10-21, Schuler picked up 33,762 at a purchase price of $0.95. This brings their total holding to 4,213,429 as of the date of the filing.

On the sell side, the most recent transaction saw Mulder unload 5,000 shares at a sale price of $1.25. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Biolase Inc. (NASDAQ:BIOL) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Here’s Who Just Picked Up Angiodynamics Inc. (NASDAQ:ANGO) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Angiodynamics Inc. (NASDAQ:ANGO) reported that Avista Capital Partners Gp, Llc. has picked up 2,333,008 of common stock as of 2017-04-14.

The acquisition brings the aggregate amount owned by Avista Capital Partners Gp, Llc. to a total of 2,333,008 representing a 6.3% stake in the company.

For those not familiar with the company, AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery. The Company’s Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, as well as other core products. The Company’s BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines.

A glance at Angiodynamics Inc. (NASDAQ:ANGO)’s key stats reveals a current market capitalization of 558.82 Million based on 36.79 Million shares outstanding and a price at last close of $15.19 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2014-04-14, Kapusta picked up 1,000 at a purchase price of $13.90. This brings their total holding to 27,005 as of the date of the filing.

On the sell side, the most recent transaction saw Burgstahler unload 384,184 shares at a sale price of $16.00. This brings their total holding to 381,406.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Angiodynamics Inc. (NASDAQ:ANGO) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Here’s Who Just Picked Up Neos Therapeutics Inc. (NASDAQ:NEOS) Shares

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Neos Therapeutics Inc. (NASDAQ:NEOS) reported that Dammeyer Rodney F has picked up 1,001,568 of common stock as of 2017-04-14.

The acquisition brings the aggregate amount owned by Dammeyer Rodney F to a total of 1,001,568 representing a 6.2% stake in the company.

For those not familiar with the company, Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.

A glance at Neos Therapeutics Inc. (NASDAQ:NEOS)’s key stats reveals a current market capitalization of 152.29 Million based on 22.56 Million shares outstanding and a price at last close of $6.80 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-08-31, Fong picked up 1,500 at a purchase price of $6.54. This brings their total holding to 1,500 as of the date of the filing.

On the sell side, the most recent transaction saw Presidio unload 213 shares at a sale price of $9.88. This brings their total holding to 39,998.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Neos Therapeutics Inc. (NASDAQ:NEOS) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

Skip to content